European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

MT Newswires Live10-19 23:13

European equities traded in the US as American depositary receipts opened the week lower late Monday morning, declining 0.65% to 1,891.99 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and medical device maker EDAP TMS (FOCL), which advanced 13% and 2.2% respectively. They were followed by internet browser company Opera (OPRA) and telecommunications company Nokia (NOK), which increased 1.1% and 0.9% respectively.

The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and pharmaceutical company Sanofi (SNY), which dropped 4.8% and 2.1% respectively. They were followed by petroleum refiner Equinor (EQNR) and telecommunications company Ericsson (ERIC), which lost 1.9% and 1.7% respectively.

The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Akari Therapeutics (AKTX), which surged 125% and 14% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Mereo BioPharma Group (MREO), which were up 1.9% and 1.6% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and utilities company National Grid (NGG), which fell 11% and 2.8% respectively. They were followed by software firm Endava (DAVA) and lender Barclays (BCS), which were off 2.4% and 2.3% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment